Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

1998 • 2,121 citations

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

2002 • 1,954 citations

Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

2001 • 1,075 citations

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

2003 • 716 citations

Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase

2005 • 481 citations

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.

1996 • 347 citations

Short-Term Changes in Ki-67 during Neoadjuvant Treatment of Primary Breast Cancer with Anastrozole or Tamoxifen Alone or Combined Correlate with Recurrence-Free Survival

2005 • 326 citations

Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

1995 • 297 citations

Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists

2005 • 275 citations

Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.

1997 • 196 citations

Human Epidermal Growth Factor Receptor—2 and Hormonal Therapies: Clinical Implications

2003 • 27 citations

Biomarker investigations from the ATAC trial: the role of TA01

2004 • 14 citations